As gene editing explodes, a new report from Goldman says Chinese groups are seizing the lead on CRISPR and CAR-T studies
Contrary to what you might believe, biopharma companies in the US are not the leaders in clinical trials using gene editing tech. While a slate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
